Prostate Cancer

Clinical Trials

Below is a list of Prostate Cancer clinical trials from the clinical trials database at Mayo Clinic.

This list includes only trials about which Mayo researchers choose to publish information. Mayo Clinic may be conducting other trials which are not in this database. Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
This study is being done to:
See if giving docetaxel chemotherapy, at the time a patient is starting hormonal therapy (treatments to lower testosterone) is more helpful than giving it only at the time the hormonal therapy is no longer working.

Hormonal therapy refers to drugs or surgical procedures such as an orchiectomy (removal of testicles) used to lower a patient's testosterone. This puts prostate cancer into remission (cancer has completely or partially gone away) in most patients as testosterone can worsen the cancer. It is the standard treatment for prostate cancer. Normally chemotherapy is reserved for when a patient's cancer starts to grow again despite having a low testosterone level. In this study the patient will either get a chemo therapy drug docetaxel when they start hormonal therapy or when/if their cancer grows with a low testosterone level. If a patient is to have chemotherapy when starting hormones for the first time, they may get chemotherapy when/if their cancer grows back with a low testosterone level.

This protocol is suggesting that a patient's doctor use docetaxel (a type of chemotherapy) if the patient's disease gets worse, even if they had received docetaxel when they started hormone therapy. A patient's doctor may try another hormone treatment before starting them on docetaxel chemotherapy. The reason for this study is to see if getting docetaxel when a patient starts hormone therapy (or within 90 days of starting hormonal therapy) and again, if their disease gets worse, is better than getting docetaxel only at the time the patient's disease gets worse. This study will tell us which way is more effective in treating a patient's disease.
Read more

SPORE in Prostate Cancer
This research study is being done to collect regular and routine follow-up information related to the outcome of treatment for prostate cancer.

This study is also being done to relate treatment outcome to measurement of substances in the blood such as PSA and other markers. Also environmental and genetic factors that might be responsible for prostate cancer are being investigated.
Read more